Document is current
Any future updates will be listed below
-
Authors
Roberts, Matthew J. https://orcid.org/0000-0003-0552-7402
Roberts, Natasha A. https://orcid.org/0000-0003-0534-8084
Pelecanos, Anita https://orcid.org/0000-0003-0197-4504
Yaxley, John W. https://orcid.org/0000-0001-6566-9037
Harley, Simon J. D.
Siriwardana, Amila R. https://orcid.org/0000-0002-6094-1246
Cullen, Karla
Prior, Marita
Lindsay, Karen
Vela, Ian https://orcid.org/0000-0002-5659-0893
Kuchel, Anna https://orcid.org/0000-0001-8580-2974
Dhiantravan, Nattakorn https://orcid.org/0000-0003-3188-450X
Thomas, Paul https://orcid.org/0000-0002-2420-0950
Pattison, David A. https://orcid.org/0000-0001-9718-5598
-
Clinical Trials BETA
Clinical trials referenced in this document:
actrn12621001185853 at Australian New Zealand Clinical Trials RegistryDocuments that mention this clinical trial
A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer
https://doi.org/10.1186/s13550-025-01265-z
-
Funding
Funding for this research was provided by:
Royal Brisbane and Women's Hospital Foundation
Sylvia and Charles Viertel Charitable Foundation
- License Information
-
More Information
Article History
Received: 2 March 2025
Accepted: 23 May 2025
First Online: 24 July 2025
Declarations
:
: The trial received institutional ethics approval from the Royal Brisbane and Women’s Hospital (RBWH) Human Research Ethics Committee (approval number HREC/2021/QRBW/75271). All participants provided informed consent.
: All participants provided informed consent.
: The authors have no relevant financial or non-financial interests to disclose.
